Advertisement

Brain Tumor Pathology

, Volume 33, Issue 1, pp 57–62 | Cite as

A case of osteoclast-like giant cell-rich epithelioid glioblastoma with BRAF V600E mutation

  • Nobuaki FunataEmail author
  • Sumihito Nobusawa
  • Ryoji Yamada
  • Nobusada Shinoura
Case Report

Abstract

Epithelioid glioblastomas (E-GBMs) are rare, highly aggressive tumors consisting of closely packed tumor cells with smooth, round cell borders and abundant eosinophilic cytoplasm. They tend to affect younger patients compared with conventional GBM. BRAF V600E mutation is characteristically found in approximately 50 % of all E-GBMs, compared with a low frequency of this mutation in conventional GBM. Here, we report an unusual case of glioma involving the right frontal lobe, basal ganglia and thalamus in an HIV-positive 30-year-old man on antiretroviral therapy. The lesion was composed of abundant discohesive, monotonous epithelioid cells with extensive necrosis, spindle and polyhedral cells, low-grade oligoastrocytoma-like areas, sarcomatous components, and numerous osteoclast-like giant cells (OLGCs) intermingled with epithelioid tumor cells. As the epithelioid cells accounted for more than one-third of the tumor, a pathological diagnosis of E-GBM was made. BRAF V600E mutation was detected in both oligoastrocytoma-like and epithelioid cell components. Similar to previously reported findings on E-GBM associated with low-grade glioma, this case suggested that low-grade astrocytic glioma with BRAF V600E mutation progressed to E-GBM. OLGCs are rarely observed in gliomas, and this is the first case report of E-GBM associated with abundant OLGC infiltration.

Keywords

Epithelioid glioblastoma BRAF V600E mutation Osteoclast-like giant cells Gliosarcoma 

Notes

Compliance with ethical standards

Conflict of interest

The authors have no conflicts of interest to declare.

References

  1. 1.
    Fuller GN, Goodman JC, Vogel H et al (1998) Epithelioid glioblastoma: a distinct clinicopathologic entity. J Neuropathol Exp Neurol 57:501CrossRefGoogle Scholar
  2. 2.
    Kleinschmidt-DeMasters BK, Aisner DL, Birks DK et al (2013) Epithelioid GBMs show a high percentage of BRAP V600E mutation. Am J Surg Pathol 37:685–698PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    Broniscer A, Tatevossian RG, Sabin ND et al (2014) Clinical, radiological, histological, and molecular characteristics of paediatric epithelioid glioblastoma. Neuropathol Appl Neurobiol 40:327–336PubMedPubMedCentralCrossRefGoogle Scholar
  4. 4.
    Kleinschmidt-DeMasters BK, Aisner DL, Birks DK et al (2015) BRAF VE1 immunoreactivity patterns in epithelioid glioblastomas positive for BRAF V600E mutation. Am J Surg Pathol 39:528–540PubMedPubMedCentralCrossRefGoogle Scholar
  5. 5.
    Schindler G, Capper D, Meyer J et al (2011) Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol 121:397–405PubMedCrossRefGoogle Scholar
  6. 6.
    Kleihues P, Burger PC, Aldape KD et al (2007) Glioblastoma. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds) WHO classification of tumours of the central nervous system, 4th edn. IARC Press, Lyon, pp 33–59Google Scholar
  7. 7.
    Nobusawa S, Hirato J, Kurihara H et al (2014) Intratumoral heterogeneity of genomic imbalance in a case of epithelioid glioblastoma with BRAF V600E mutation. Brain Pathol 24:239–246PubMedCrossRefGoogle Scholar
  8. 8.
    Tanaka S, Nakada M, Nobusawa S et al (2014) Epithelioid glioblastoma arising from pleomorphic xanthoastrocytoma with the BRAF V600E mutation. Brain Tumor Pathol 31:172–176PubMedCrossRefGoogle Scholar
  9. 9.
    Kleinschmidt-DeMasters BK, Alassiri AH, Birks DK et al (2010) Epithelioid versus rhabdoid glioblastomas are distinguished by monosomy 22 and immunohistochemical expression of INI-1 but not claudin 6. Am J Surg Pathol 34:341–354PubMedCrossRefGoogle Scholar
  10. 10.
    Rodriguez FJ, Scheithauer BW, Giannini C et al (2008) Epithelial pseudoepithelial differentiation in glioblastoma and gliosarcoma. A comparative morphologic and molecular genetic study. Cancer 113:2779–2789PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    Frank S, Cordier D, Tolnay M et al (2009) A 28-year-old man with headache, visual and aphasic speech disturbances. Brain Pathol 19:163–166PubMedCrossRefGoogle Scholar
  12. 12.
    Shishido-Hara Y, Kurata A, Fujiwara M et al (2010) Two cases of breast carcinoma with osteoclastic giant cells: are the osteoclastic giant cells pro-tumoural differentiation of macrophages? Diagn Pathol 5:55PubMedPubMedCentralCrossRefGoogle Scholar
  13. 13.
    Bautista F, Paci A, Minard-Colin V et al (2014) Vemurafenib in pediatric patients with BRAF V600E mutated high-grade gliomas. Pediatr Blood Cancer 61:1101–1103PubMedCrossRefGoogle Scholar
  14. 14.
    Robinson GW, Orr BA, Gajjar A (2014) Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy. BMC Cancer 14:258PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© The Japan Society of Brain Tumor Pathology 2015

Authors and Affiliations

  • Nobuaki Funata
    • 1
    Email author
  • Sumihito Nobusawa
    • 2
  • Ryoji Yamada
    • 3
  • Nobusada Shinoura
    • 3
  1. 1.Department of PathologyCancer and Infectious Disease Center Tokyo Metropolitan Komagome HospitalTokyoJapan
  2. 2.Department of Human PathologyGunma University Graduate School of MedicineMaebashiJapan
  3. 3.Department of NeurosurgeryCancer and Infectious Disease Center Tokyo Metropolitan Komagome HospitalTokyoJapan

Personalised recommendations